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Abstract The last 10 years have seen enormous progress
in the field of paraganglioma and pheochromocytoma
genetics. The identification of the first gene related to par-
aganglioma, SDHD, encoding a subunit of mitochondrial
succinate dehydrogenase (SDH), was quickly followed by
the identification of mutations in SDHC and SDHB. Very
recently several new SDH-related genes have been dis-
covered. The SDHAF2 gene encodes an SDH co-factor
related to the function of the SDHA subunit, and is currently
exclusively associated with head and neck paragangliomas.
SDHA itself has now also been identified as a paragangli-
oma gene, with the recent identification of the first mutation
in a patient with extra-adrenal paraganglioma. Another
SDH-related co-factor, SDHAF1, is not currently known to
be a tumor suppressor, but may shed some light on the
mechanisms of tumorigenesis. An entirely novel gene
associated with adrenal pheochromocytoma, TMEM127,
suggests that other new paraganglioma susceptibility genes
may await discovery. In addition to these recent discoveries,
new techniques related to mutation analysis, including
genetic analysis algorithms, SDHB immunohistochemistry,
and deletion analysis by MLPA have improved the effi-
ciency and accuracy of genetic analysis. However, many
intriguing questions remain, such as the striking differences
in the clinical phenotype of genes that encode proteins with
an apparently very close functional relationship, and the
lack of expression of SDHD and SDHAF2 mutations when
inherited via the maternal line. Little is still known of the
origins and causes of truly sporadic tumors, and the role of
oxygen in the relationships between high-altitude, familial
and truly sporadic paragangliomas remains to be elucidated.
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Introduction
Prior to the year 2000, knowledge of the genetics of para-
ganglioma and pheochromocytoma was confined to mutations
of the VHL, RET and NF1 genes. The identification of muta-
tions in the succinate dehydrogenase subunit D gene (SDHD)
in patients with head and neck paraganglioma [1] was there-
fore a major breakthrough. The association of paraganglioma
with mutations in SDHD, and later with mutations in other
SDH subunits, has helped elucidate both the role of the
mitochondrial SDH complex and intermediary metabolism in
tumorigenesis. The subsequent discovery of SDH mutations
in patients with pheochromocytomas and extra-adrenal para-
gangliomas [2] led to a recognition that paragangliomas and
pheochromocytomas share not only similar cellular origins,
but can also have a comparable genetic basis.
Paragangliomas of the head and neck are generally
benign tumors that arise in the paraganglion tissue associ-
ated with the autonomic nervous system. Paragangliomas
most frequently arise in the head and neck region, as carotid
body tumors in the carotid bifurcation (approximately 80%).
Other frequently seen locations within the head and neck
region are along the jugular bulb or tympanic nerve (17.5%),
or the paraganglia along the vagal nerve (4.5%) [3].
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Pheochromocytomas and extra-adrenal paragangliomas
are tumors associated with the sympathetic nervous system,
are commonly described as sympathetic paragangliomas
(sPGLs), and show a close embryological and physiologi-
cal relationship to head and neck paragangliomas. They are
most commonly derived from the chromaffin cells of the
adrenal medulla (pheochromocytoma), but approximately
10–20% occur elsewhere in the abdomen [4], but can occur
from the neck to the pelvic floor in any of the sympathetic
paraganglia. Extra-adrenal sympathetic paragangliomas
show a greater degree of malignancy than either pheo-
chromocytomas or head and neck paragangliomas [5].
Here we discuss recent advances in the understanding of
the genetic basis of both head and neck paragangliomas
and pheochromocytomas, and further developments rele-
vant to the genetic diagnosis of these tumors.
Genetics
Presently, causative gene mutations can be identified in
around 32% of paraganglioma-pheochromocytomas [6].
Hereditary tumor syndromes which have pheochromocytoma
within their spectrum include the multiple endocrine neopla-
sia syndromes, MEN2A and MEN2B, caused by mutations
of the RET (Rearranged in Transfection) proto-oncogene,
subtypes of von Hippel-Lindau (VHL) disease, caused by
mutations of the VHL tumor suppressor gene, and neurofi-
bromatosis type 1 (NF1) resulting from mutations of the NF1
tumor suppressor gene [7]. These syndromes account for
around 17% of cases [6] but are rarely associated with head
and neck or extra-adrenal paragangliomas.
More recently, mutations in genes associated with the
mitochondrial succinate dehydrogenase (SDH) complex
(SDHA, SDHB, SDHC, SDHD and SDHAF2) have been
shown to cause head and neck paragangliomas, extra-adre-
nal paragangliomas, and pheochromocytomas (Table 1) [1,
2, 8–11]. These genes account for the remaining 15% of
cases [6]. All of these genes are tumor suppressors, showing
loss of heterozygosity (LOH), the loss of the normal allele in
the tumor, in conjunction with the germline mutation. This
results in loss of a protein subunit, which in turn destabilizes
the SDH complex and abolishes its enzymatic activity [12].
Succinate dehydrogenase is an enzyme of the mito-
chondrial tricarboxylic acid cycle, and also plays an
important role as the complex II component of the electron
Table 1 Summary of genes, known protein functions and related syndromes
Gene Locus Protein function Gene mechanism No. of
unique
mutationsa
Syndrome Primary locations
SDHD 11q23 One of the two transmembrane
subunits of Complex II of the
respiratory chain
Autosomal
dominant with
LOH ?
imprinting
110 Hereditary
paraganglioma/
pheochromocytoma
Head and neck;
parasympathetic trunk
SDHB 1p36.1-
p35
The iron-sulfur protein catalytic
subunit of Complex II
Autosomal
dominant with
LOH
175 Hereditary
paraganglioma/
pheochromocytoma
Abdominal/thoracic
paraganglia, adrenal;
sympathetic trunk
SDHC 1q23.3 One of the two transmembrane
subunits of Complex II of the
respiratory chain
Autosomal
dominant with
LOH
34 Hereditary
paraganglioma/
pheochromocytoma
Head and neck;
parasympathetic trunk
SDHAF2 11q12.2 Mitochondrial assembly factor
for Complex II—interacts
directly with SDHA
Autosomal
dominant with
LOH ?
imprinting
1 Hereditary
paraganglioma/
pheochromocytoma
Head and neck;
parasympathetic trunk
SDHA 5p15 The flavoprotein catalytic subunit
of Complex II
Autosomal
dominant with
LOH
1 Hereditary
paraganglioma/
pheochromocytoma
Abdominal paraganglia,
sympathetic trunk
SDHA 5p15 The flavoprotein catalytic subunit
of Complex II
Autosomal
recessive
7 Mitochondrial
encephalopathy/
Leigh Syndrome
Systemic
SDHAF1 19q13.12 Mitochondrial assembly factor
for Complex II. Interacts
directly with SDHB?
Autosomal
recessive
2 Infantile
leukoencephalopathy
Systemic
TMEM127 2q11.2 Transmembrane protein involved
in protein trafficking
Autosomal
dominant with
LOH
8 Hereditary
pheochromocytoma
Adrenal; sympathetic
trunk
a Number of mutations derived from the literature or the TCAC gene mutation database [34]
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transport chain, contributing to the generation of ATP by
oxidative phosphorylation. These combined roles place
SDH at the center of two of the essential energy producing
processes of the cell. SDHA is a flavoprotein, and SDHB,
an iron-sulfur protein, and together they form the main
catalytic domain, while SDHC and SDHD are the mem-
brane-anchoring subunits of SDH and play a role in passing
electrons through the electron transport chain. Despite the
fact that SDH proteins are all components of the same
protein complex, mutations lead to clear differences in
clinical phenotype. The molecular basis for this clinical
divergence is not currently known.
SDHD
Researchers in the Netherlands were the first to success-
fully tackle the genetics of head and neck paraganglioma
[13–18] and they were greatly assisted by the unusual
social and demographic history of the country. Until rela-
tively recently, the Netherlands was characterized by sig-
nificant religious, social, and geographic obstacles to
intermarriage, leading to the creation of many genetically
isolated populations [19]. Such populations facilitate the
proliferation of founder mutations, one of them being the
well-known Dutch SDHD founder mutation, p. Asp92Tyr
[20]. The increased prevalence of this and other SDHD
founder mutations, relative to SDHB mutations, facilitated
the initial mapping of the SDHD locus [13, 14].
The subsequent identification of the gene in 2000 [1]
represented a significant discovery as it was the first time
that a mitochondrial protein was show to be a tumor sup-
pressor. It was also the first protein with a role in inter-
mediary metabolism to be directly linked to tumorigenesis.
Mutations in SDHD most frequently result in benign head
and neck paragangliomas and are much less commonly
associated with sympathetic paragangliomas and adrenal
pheochromocytomas [21]. The proportion of SDHD
mutation carriers that will develop a tumor (penetrance) is
high (87–100%), although not all carriers with a tumor will
develop additional tumor-related symptoms [22, 23].
SDHB
The identification of mutations in SDHD as a cause of
hereditary paraganglioma syndrome quickly led to the dis-
covery of the role of other SDH subunits. SDHB plays a
major role in hereditary paraganglioma syndrome [2], and is
now known to be a significant cause of adrenal pheochro-
mocytomas, but is chiefly associated with extra-adrenal
paragangliomas [6]. Since its discovery, SDHB has been
found to be the dominant gene in hereditary paraganglioma
syndrome in many parts of the world, despite a relatively
low penetrance of SDHB mutations of 25–40% [24–26].
Due to their lower penetrance, SDHB mutations are often
found in apparently sporadic patients [27]. SDHB mutations
primarily predispose to sPGLs, and around 20% of SDHB
mutation carriers will develop metastatic disease [5, 6].
SDHC
SDHC was the second SDH subunit gene identified as a
cause of paragangliomas [11]. Paragangliomas due to
mutations in SDHC are much rarer than SDHB- and SDHD-
related paragangliomas, accounting for less than 1% of all
patients in a recent study [6]. SDHC mutations result pri-
marily in head and neck paragangliomas, but have also
been identified in patients with sympathetic paraganglio-
mas [28, 29].
SDHAF2
While the role of the SDHB, SDHC and SDHD genes in
paraganglioma/pheochromocytoma has been known for a
number of years, several novel SDH-related genes have only
been identified very recently. The first was a gene encoding a
novel protein involved in the addition of the flavin-adenine
dinucleotide (FAD) prosthetic group to form the active
SDHA flavoprotein [10]. While the approximate location of
this paraganglioma-associated gene had been known for over
a decade, referred to as PGL2 locus [15, 16], a yeast screen of
respiration deficient mutants facilitated the fortuitous dis-
covery of a conserved mitochondrial protein of unknown
function that physically associated with the SDHA flavo-
protein. Initially named SDH5, the succinate dehydrogenase
complex assembly factor 2 (SDHAF2) was shown to be
essential for the correct flavination of SDHA and function of
the SDH complex. A missense mutation of SDHAF2
c.232G[A (p.Gly78Arg) identified in a large Dutch head and
neck paraganglioma kindred results in the loss of SDHA
flavination and activity of the SDH complex [10].
In a follow-up study with the joint aims of identifying
new mutation carriers and assessing the frequency of
SDHAF2 mutations amongst 443 paraganglioma and
pheochromocytoma patients, it became clear that mutations
in this gene make a very modest contribution to the overall
genetic burden in these syndromes [8]. No mutations of
SDHAF2 were identified in any patient with a pheochro-
mocytoma, and all currently affected mutation carriers
have head and neck paraganglioma exclusively. Only one
additional SDHAF2-related family was identified, which
interestingly carried the exact mutation, p.Gly78Arg, pre-
viously found in the Netherlands, but without evidence of a
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familial relationship to the Dutch kindred [8]. Although
apparently a simple loss of function mutation in yeast [10],
the recurrence of this mutation and absence of other
mutations [8, 30] may suggest that the SDHAF2 protein
with the specific p.Gly78Arg mutation retains residual
activity, allowing the protein to participate in other, cur-
rently unknown, cellular activities, most feasibly the
addition of FAD prosthetic groups to other flavoproteins.
A striking aspect of SDHAF2 mutations, and the prob-
able explanation for the rapid identification of all mutation
carriers, is the very high penetrance. Of the 42 identified
mutation carriers thought to be at risk, 37 are known to
have developed a tumor. All currently unaffected mutation
carriers are under the age of 45. This level of penetrance
will usually lead to a familial presentation and such fam-
ilies will have already come to the attention of clinicians.
Seven mutation carriers are known to have inherited the
mutation via the maternal line, and are not thought to be at
risk of tumor development (see ‘‘Inheritance’’ below).
The studies above suggest that SDHAF2 mutation
screening should only be considered in patients who suffer
exclusively from head and neck paragangliomas, who have
familial antecedents, multiple tumors, or a very young age
of onset, and in whom the SDHB, SDHC and SDHD genes
have been shown to be negative for mutations and deletions
by sequencing and multiplex ligation-dependent probe
amplification (MLPA).
SDHA
The identification of SDHAF2 as a paraganglioma-related
tumor suppressor that interacts with SDHA was unex-
pected, as SDHA itself was the only SDH subunit gene not
known to be mutated in paraganglioma cases. SDHA is the
largest gene and protein of the SDH complex and is the
major catalytic subunit of the enzyme. For 10 years fol-
lowing the discovery of SDHD, it remained a mystery why
no mutations of SDHA could be found in paraganglioma
patients, a mystery which deepened with the identification
of SDHAF2 as a paraganglioma-related tumor suppressor
gene. Recently the first SDHA mutation was reported,
(c.1765C[T, p.Arg589Trp—exon 13) in a patient with a
catecholamine secreting extra-adrenal paraganglioma [9].
This patient had no family history of paraganglioma or any
related endocrine syndrome.
It remains unclear why SDHA mutations in paragan-
gliomas are so rare, but the patient above may suggest that
SDHA mutations show reduced penetrance and most
mutation carriers escape the development of clinical
symptoms. Equally, and as suggested above for SDHAF2,
the scarcity of SDHA mutations could be attributable to a
secondary cellular function of SDHA, leading to intolerance
for missense and truncating mutations that eliminate all
enzyme activity.
The most stable of the SDH proteins when soluble,
SDHA has been reported to be a component of a mito-
chondrial ATP-sensitive potassium channel [31]. While
SDHB also seemed to be involved in this complex, the
main protein interaction was between SDHA and the
mitochondrial ATP-binding cassette protein 1 (mABC1),
and the complex could be inhibited by 3-nitropropionate
(NPA), a specific inhibitor of SDHA [32]. Whether the
maintenance of this complex is essential to cell viability
remains to be determined.
Alternatively, if we assume that an LOH event which
deletes the remaining normal allele is required for tumor-
igenesis, loss of essential genes in the proximity of SDHA
may not be tolerated, or other local genomic factors may be
preventing the secondary LOH event. An exact molecular
description of the LOH event in the case described by
Burnichon et al. [9] and in any subsequent cases may
provide useful insights.
A few rare cases of congenital SDHA deficiency due to
homozygous recessive mutations are known [33–35].
While the patients themselves tend to be severely affected
by developmental abnormalities or cardiomyopathy early
in life, due to mitochondrial deficiency, the heterozygous
parents of these patients have never been reported to
develop paraganglioma, perhaps suggesting that LOH
events are indeed rare in conjunction with mutations of
SDHA.
Mutations seen in these patients are generally missense
and the only known truncating mutation in a patient was
found together with a missense mutation on the opposing
allele [36], suggesting that complete loss of SDHA func-
tion may not be compatible with life.
Whether the patient described by Burnichon et al. [9]
will prove to be first of many paraganglioma cases related
to SDHA mutations is presently unclear. The current sig-
nificance of SDHA in the clinical management of para-
ganglioma-pheochromocytoma is minimal, but this may
change if future studies identify additional mutation
carriers.
SDHAF1
The identification of SDHAF2 as a paraganglioma gene
underlines the curious fact that another recently identified
gene is not currently known to be involved in paragangli-
oma, but may nevertheless further our understanding of the
role of SDH in paraganglioma formation. Succinate
dehydrogenase complex assembly factor 1 (SDHAF1) [37]
is a novel LYR-motif protein; the first SDH assembly
factor identified in any organism, and is located within the
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mitochondrial matrix. Identified in consanguineous fami-
lies of Turkish and Italian origin, homozygous mutations of
the SDHAF1 gene result in infantile leukoencephalopathy
in affected children, and symptoms include rapidly pro-
gressive psychomotor regression beginning in the first year
of life, reminiscent of the clinical symptoms seen in
homozygous SDHA mutations carriers [38]. Patients show
defective succinate dehydrogenase (complex II), with only
20–30% residual activity in muscle and fibroblasts, and the
accumulation of lactate and succinate in the brain white
matter. Disruption of the homologous gene or expression of
the mutated gene in yeast caused SDH deficiency and
failure of oxidative phosphorylation-dependent growth.
Because the LYR tripeptide motif found in SDHAF1 is
also seen in several iron-related proteins and may be a
signature for proteins involved in Fe–S metabolism, this
protein may well be associated with the SDHB subunit.
Loss of SDHB is currently thought to be central to
tumorigenesis in paragangliomas [39], but none of the
parents in SDHAF1 families, who are heterozygous muta-
tion carriers, have been reported to develop paraganglio-
mas. The explanation for the lack of tumor development in
these mutation carriers and heterozygous SDHA mutation
carriers may lie in the biochemical activity of SDH-com-
plex II. SDHA homozygous mutation carriers generally
show retention of complex II activity of at least 20% (range
20–61%) [33, 35], and likewise, homozygous SDHAF1
mutation carriers show 20–30% residual activity. In con-
trast, SDH-related tumors, including SDHD [12], SDHB
[40], SDHA [9] and SDHAF2 [12] carry an inactivating
mutation which, combined with the loss of the wild type
allele (LOH), results in almost complete loss of activity. As
SDHAF1 and most SDHA mutations do not eliminate all
enzyme function, even allowing for LOH in a specific cell,
a residual activity of 10–30% is apparently sufficient to
prevent the development of paragangliomas.
A further interesting aspect of the biochemical profile of
SDHAF1 and SDHA mutation carriers is the accumulation
of succinate. In both cases succinate will accumulate [37,
41] and can lead to the nuclear translocation of hypoxia-
inducible factor 1 (HIF-1) [41]. The nuclear translocation
of HIF-1 may be an important mechanism in triggering
tumorigenesis in paraganglioma progenitor cells [42, 43],
but its occurrence in SDHAF1 and SDHA mutation carriers
may suggest that complete loss of SDH activity is required
to achieve levels of succinate accumulation sufficient to
drive HIF-1 translocation to the extent needed to initiate
tumorigenesis. For a detailed discussion of these and other
recent developments in the understanding of the molecular
basis of tumorigenesis, we refer readers to a recent review
[43].
Although none of the heterozygous mutation carriers
in SDHAF1 families currently seem susceptible to the
development of paragangliomas-pheochromocytomas, the
recent example of SDHA [9] emphasizes that no SDH-
related gene can be entirely excluded when one is con-
sidering the genetics of these tumors.
TMEM127
In addition to the recently reported genes related to succi-
nate dehydrogenase, a novel tumor suppressor gene asso-
ciated with a clinical phenotype of exclusively adrenal
pheochromocytoma has also been described [44]. The gene
encodes a putative transmembrane protein, TMEM127, and
is found on chromosome 2q11. TMEM127 is a highly
conserved and broadly expressed protein with three trans-
membrane regions, but has no known functional domains.
Transfection experiments showed that the protein is found
in both the plasma membrane and the cytoplasm, and sug-
gested that TMEM127 may participate in protein trafficking
between the plasma membrane, golgi and lysosomes.
Previous gene expression studies have indicated that
pheochromocytomas fall into two broad categories based on
the transcriptional profile [45], which may translate to the
molecular pathways leading to tumorigenesis. SDH and
VHL associated tumors show a signature of angiogenesis,
hypoxia, enhanced expression of the extracellular matrix,
and reduced expression of components of the oxidative
response and tricarboxylic cycle. Tumors linked to NF1 or
RET mutations show an upregulation of biological pathways
including genes that mediate translation initiation, protein
synthesis, and kinase signaling, and are both associated with
the RAS/RAF/MAP kinase signaling pathway [45].
TMEM127-related pheochromocytomas show a tran-
scriptional profile similar to NF1 and RET related tumors
[44]. However, neither RAS activation nor AKT phos-
phorylation was seen, indicating that TMEM127 loss is not
identical to either NF1 or RET. The authors focused on the
mammalian target of rapamycin (mTOR), which is dereg-
ulated on loss of NF1, and could show that the C1 mTOR
complex is specifically affected by TMEM127 knockdown,
leading to increased phosphorylation of targets of mTORC1.
Knockdown of TMEM127 also resulted in larger cells with
higher rates of proliferation. Pheochromocytomas carrying a
TMEM127 mutation showed hyperphosphorylation of
mTOR effector proteins, all these data together indicating
that TMEM127 is a negative regulator of mTOR.
The authors were able to identify mutations in 4 out of
12 families without known mutations in other susceptibility
genes, and in 3 of 83 apparently sporadic patients. Of the
seven distinct germline mutations identified, six were
truncating, and the deletion of the wild-type allele in tumor
DNA indicates that this is a bone fide tumor suppressor
gene.
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The identification of TMEM127 underlines that there are
several pathways that can lead to adrenal, extra-adrenal,
and head and neck paragangliomas. Whether there are
important links between the essential molecular pathways
of NF1, RET, and TMEM127 on the one hand and the
VHL and SDH-related proteins on the other, is presently
unclear, but hypoxia can regulate both HIF-1 and mTORC1
[46], perhaps related to expression of BCL2/Adenovirus
E1B 19-KD protein-interacting protein 3 (BNIP3) [47]. As
each of these genes is associated with patterns of biological
and clinical expression that are not yet understood, it is
clear that we are only at the beginnings of our knowledge
of these syndromes.
Inheritance
Inheritance of paraganglioma syndrome differs signifi-
cantly dependent on the gene involved. While SDHB- and
SDHC-linked paraganglioma families show normal auto-
somal dominant inheritance, SDHD and SDHAF2 linked
families show an exclusively paternal transmission of
tumor susceptibility [10, 18]. The recognition of this phe-
nomenon was made possible by the same social and
demographic factors in the Netherlands that facilitated the
initial mapping of the SDHD locus, and specifically by the
increased prevalence of SDHD mutations, relative to SDHB
mutations. Although mutations in SDHD and SDHAF2 can
be inherited via the maternal and paternal lines, tumor
formation following maternal transmission of a mutation is
extremely rare [18, 48].
The failure of maternally transmitted mutations to
initiate tumorigenesis initially suggested that an imprinted
gene expressed only from the paternal allele could be the
underlying cause of the tumor [18]. The subsequent iden-
tification of SDHD, with its central role in cell biology,
called this assumption into question. It was also established
that the gene does not show mono-allelic expression, at
least in the tissues analyzed to date [1, 49]. The concept of
gene expression of SDHD exclusively from the paternal
allele is also contradicted by the normal development of
mutation carriers with a paternally inherited mutation.
The additional occurrence of this phenomenon in para-
ganglioma families linked to SDHAF2, (like SDHD, located
on chromosome 11), while it is absent in SDHB- and SDHC-
related tumors (both genes located on chromosome 1),
suggested that chromosomal location could be a factor in
SDHD and SDHAF2 related tumors.
It is known that the entire maternal copy of chromosome
11 is lost in many paragangliomas [49–51]. Although
SDHD and SDHAF2 themselves seem not to be imprinted,
the main cluster of imprinted genes in the human genome is
located on the same chromosome, at 11p15.5. This
suggests a model [48, 49] in which a maternally expressed,
paternally imprinted gene is an essential initiator or mod-
ifier of tumor development in these syndromes. Indeed, the
only report to date that has claimed to show the maternal
transmission of tumor susceptibly together with an SDHD
mutation showed that the patient had also acquired an
altered methylation profile and therefore probably an
altered imprinted status of H19, a known paternally
imprinted tumor suppressor gene on 11p15 [48, 52].In
addition, it is known that VHL-related pheochromocytomas
[53, 54] also show loss of the maternal copy of the chro-
mosome 11p15.5 region specifically, indicating that this
model may have wider importance.
High altitude paraganglioma
Long before the identification of any of the genes now
known to play a role in paraganglioma, it was recognized
that living at high altitude can have a profound influence on
the development of carotid body hyperplasia and carotid
body tumors [55–57]. A number of mammalian species are
known to develop pronounced hyperplasia or tumors with a
prevalence of up to 10% in humans and up to 40% in
bovines [58, 59], in contrast to an estimated low altitude
prevalence of head and neck paraganglioma of 1 in 500,000
or less.
This increased prevalence and the central role of the
carotid body in oxygen sensing suggested a role for oxygen
sensing in the tumorigenesis of paragangliomas. The
identification of succinate dehydrogenase and subsequent
molecular studies has affirmed this link. A number of
studies have linked the central mediator of cellular
hypoxia, HIF-1, to defects in succinate dehydrogenase
[60]. These studies postulate that a so-called ‘pseudo-
hypoxia’ results from the inhibition of succinate dehydro-
genase, leading to the accumulation of succinate, resulting
in the activation of HIF-1 through the inhibition of prolyl
hydroxylase-mediated degradation [42, 61]. The HIF-1
transcription factor complex [62] initiates the transcription
of a range of genes that mediate an adaptive response to
reduced oxygen. How the activation of the HIF-1 protein
may lead to the initiation of tumorigenesis in the carotid
body and the exact relation of physiological hypoxia to
molecular ‘pseudo-hypoxia’ awaits further investigation.
Despite this suggestive link, the possible role of succinate
dehydrogenase mutations in high altitude paraganglioma
cases has received little attention and the first genetic
analysis failed to identify any mutations [63]. Recently,
Cerecer-Gil et al. [64] identified a family with two SDHB-
linked cases of high altitude paraganglioma, residing at
elevations of up to 2,200 m. These are the first cases to link
high altitude paraganglioma to mutations of the succinate
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dehydrogenase genes. While the occurrence of paragan-
glioma in this family could be purely coincidental to their
place of residence, two factors indicated that elevation may
be playing a role in the expression off these tumors. One of
the patients showed a remarkably aggressive recurrent
tumor, which achieved a volume almost equivalent to the
original tumor within 2 months of excision. This behavior
is in sharp contrast with the indolent growth pattern nor-
mally seen in head and neck paragangliomas, with a mean
doubling rate of 4.2 years [65]. In addition, both patients
developed head and neck tumors, while abdominal tumors
occur much more frequently in SDHB mutation carriers.
The identification of SDHB mutations in high altitude
paraganglioma may serve to renew interest in this fasci-
nating but underappreciated field of paraganglioma
research, and refocus attention on the role of oxygen levels
in the initiation and development of these tumors.
New strategies in mutation analysis
The importance of the SDH-related genes in para-
ganglioma-pheochromocytoma has led to extensive genetic
screening of patients, even in the absence of clear familial
antecedents. In patients with pheochromocytomas, in
addition to the SDH genes, the RET and VHL genes should
also be screened. The costs involved in analyzing all of
these genes can be considerable, and are increasing with
each new gene identified. Efforts have been made to use
clinical data to derive algorithms to guide rational genetic
testing, with the aims of efficiency and cost reduction
[6, 21, 66]. Perhaps the most comprehensive of these is that
proposed by Mannelli et al. [6], but even this is now in
need of updating. Such algorithms are now widely used and
assist the rapid identification of mutation carriers, but many
patients may provide few useful clinical parameters, or
may not conform to the rather broad criteria of these
algorithms.
Mutation analysis is generally carried out using DNA
sequencing, but this technique can rarely detect large
deletions. Both MLPA [67] and similar multiplex PCR
methods [68] have been applied in SDH deletion analysis,
and have led to the recognition that deletions can represent
up to 10% of all mutations [69].
While algorithms have improved the efficiency of
genetic testing, recently a supplementary approach has
been developed with the use of SDHB immunohisto-
chemistry. As originally noted by Douwes Dekker et al.
[12], paragangliomas show loss of staining for the iron
protein component of SDH, encoded by SDHB. This find-
ing was subsequently explored by van Nederveen et al. [39]
who showed that in a series of 220 paragangliomas and
pheochromocytomas, 102 tumors with known mutation of
one of the SDH genes were negative for SDHB staining
while RET, VHL and NF1 cases were uniformly positive.
Only six cases were found to be negative and not explained
by a known mutation in one of the SDH genes. This
translates to a sensitivity of 95% (C.I. 87–100%) and
specificity of 84% (C.I. 60–97%).
The utility of this approach was subsequently confirmed
in an independent series of tumors by Gill et al. [70] and
was also shown to be useful in identifying the gastroin-
testinal stromal tumor (GIST) component of the Carney
triad (CT) [71]. Showing that a GIST is a legitimate con-
stituent of this tumor syndrome would potentially allow
earlier diagnosis, when compared to current methods which
focus on clinical criteria and require the co-occurrence of
paraganglioma and pulmonary chondroma. These authors
also showed that some cases of apparently sporadic GISTs
also show loss of SDHB staining and propose that these
represent a new subtype of GISTs.
The development of a reliable SDHB immunohisto-
chemical procedure and the demonstration that SDHB
staining can accurately distinguish SDH-related cases from
other groups represents an important advance, where tumor
material is available. As head and neck paragangliomas are
often not operated for a considerable period after initial
diagnosis, while most pheochromocytomas will be removed
upon diagnosis, phaeochromocytomas represent the most
useful group of tumors for the application of this technique.
Conclusion
The last 10 years have seen enormous progress in the field
of head and neck paraganglioma and pheochromocytoma
genetics. Six new genes have been added to a list that
previously included only VHL, RET and NF1, and the
number of patients in whom a gene mutation can be
identified has doubled, and now stands at around 30–35%.
New techniques related to mutation analysis, including
analysis algorithms, MLPA and SDHB immunohisto-
chemistry, have improved the efficiency and accuracy of
genetic analysis.
The identification of mutations in SDHAF2 has revealed
that proteins ancillary to succinate dehydrogenase can also
be tumorigenic, and the belated identification of a mutation
in SDHA in a paraganglioma patient has demonstrated that
no SDH-related gene can be entirely excluded from con-
sideration when thinking about the genetics of these tumor
syndromes.
Finally, the recent identification of TMEM127 by Dahia
et al. [44] has shown that entirely novel genes may be
related to these tumor syndromes and suggests that others
may await discovery.
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